0001437749-26-008612
SEC filingAXT's 2025 revenue fell 11.1% to $88.3M and gross margin contracted to 12.7% from 24.0%, driven by China's InP export permit requirements and deliberate germanium substrate sales reductions.
AXT, Inc. reported total revenue of $88.3 million for the fiscal year ended December 31, 2025, an 11.1% decrease from $99.4 million in 2024. This decline was primarily driven by a $8.8 million, or 13.1%, decrease in substrate sales, specifically lower sales of germanium wafers due to a deliberate reduction in sales amid increased raw material costs, and the impact of Chinese export permit requirements on indium phosphide (InP) substrates announced on February 4, 2025. Raw materials revenue also decreased by $2.2 million, or 6.9%, mainly from lower purified gallium sales. Geographically, North American revenue suffered the most, falling 77.5% to $1.7 million, directly due to the inability to ship InP substrates to the U.S. without permits.
Gross profit decreased by $12.6 million, or 52.8%, to $11.2 million, with gross margin contracting significantly to 12.7% from 24.0% in the prior year. Management attributed the margin compression to lower revenue spreading fixed costs over fewer units and manufacturing variances, particularly in the first half of the year. Selling, general and administrative expenses remained relatively flat at $24.2 million, while research and development expenses decreased by $5.5 million, or 37.8%, to $9.0 million, primarily due to reduced material usage for development projects. The company reported a net loss of $23.2 million for 2025, compared to a net loss of $11.8 million in 2024.
The company operates one segment with two product lines: specialty material substrates and raw materials. Substrate revenue, which includes InP, GaAs, and Ge wafers, was $58.9 million in 2025. The decline was led by germanium wafers, where sales were intentionally reduced due to raw material cost increases that made pricing uncompetitive. InP revenue also declined despite increased demand, as export permit requirements restricted shipments. GaAs revenue saw a slight decline. The raw materials line, generating $29.4 million, experienced a decrease primarily from lower purified gallium sales, partially offset by increased revenue from pBN crucibles and pBN-based OLED manufacturing tools sold by the BoYu subsidiary.
From a geographic perspective, China remained the largest market at 62% of total revenue, though sales there decreased by 1.9%. Europe and Taiwan also saw declines of 19.0% and 7.5%, respectively. The most dramatic shift was in North America, where revenue fell to just 2% of the total from 8% in the prior year, highlighting the severe impact of trade restrictions on the company's primary revenue generator for that region.
Management's outlook is heavily clouded by geopolitical and trade uncertainties. The primary challenge is securing export permits from China's Ministry of Commerce for InP substrates, which were added to the export control list on February 4, 2025. While initial permits for shipments to certain customers in Europe and Japan were received in June 2025, the timing for permits to ship to the U.S. remains uncertain and beyond the company's control. The fluid nature of U.S. tariffs, which reached 70% on wafer substrates before a Supreme Court ruling invalidated some of them, adds further unpredictability. Management expects that tariffs and export regulations will negatively impact revenues, profitability, and cash flows.
Strategically, the company completed a public offering in December 2025, raising net proceeds of $93.9 million. The intended use of these funds is to financially support the subsidiary Tongmei in increasing its manufacturing capacity for InP substrates for export worldwide, along with research and development and general corporate purposes. The company ended the year with a strong liquidity position of $128.4 million in cash, restricted cash, and cash equivalents, which management believes is adequate to meet operating needs and capital expenditures over the next twelve months.
AXT, Inc. reported a significant increase in liquidity as of December 31, 2025. Cash, restricted cash, and cash equivalents totaled $128.4 million, a substantial rise from $33.8 million at the end of 2024. This increase was primarily driven by $95.2 million in net proceeds from the issuance of common stock. The company's total debt stood at $68.0 million, with $62.8 million classified as short-term loans and $5.2 million as long-term. Short-term loans consisted of $58.5 million in bank loans from various Chinese financial institutions and $4.3 million representing the current portion of long-term debt. The company's total stockholders' equity was $296.6 million. Inventory was reported at $81.7 million, net of a significant $28.4 million reserve for excess and obsolete inventory, highlighting potential demand forecasting challenges.
The Notes do not disclose a detailed table of purchase commitments. However, the company has operating lease liabilities totaling $2.0 million, with $0.6 million due within one year. The company also has a cross-license agreement requiring annual payments through 2029, though the expense was not considered material. AXT has cooperation agreements with local governments in Dingxing and Kazuo, China, targeting total investments of approximately $90 million and $15 million, respectively, in value, assets, and capital, though these are described as good faith covenants without specific penalties or deadlines.
Capital allocation activities were dominated by financing and debt management. The company raised $95.2 million in net proceeds from common stock issuance. In terms of debt, AXT's subsidiaries drew $58.6 million in new short-term bank loans and repaid $48.6 million. Capital expenditures for property, plant, and equipment were $6.0 million. The company did not pay dividends on its common stock but has $2.9 million in cumulative unpaid dividends on its Series A preferred stock. A previously authorized stock repurchase program has $2.7 million remaining, though no shares were repurchased in 2025.
The company operates in a single segment for the design, development, manufacture, and distribution of semiconductor substrates and raw materials. Revenue is disaggregated by product type and geography. Substrate revenue was $58.9 million (67% of total), and raw materials revenue was $29.4 million (33%). Geographically, China was the largest market at $55.1 million, followed by Taiwan ($13.0 million) and Europe ($11.2 million). North American revenue was $1.7 million. Long-lived assets are heavily concentrated in China, totaling $162.8 million, compared to $1.0 million in North America.
The dominant risk for AXT is the escalating US-China trade conflict. China's February 2025 addition of indium phosphide (InP) substrates to its export control list created a major operational hurdle, as InP is the primary revenue generator for US imports. While initial permits were received in June 2025 for European and Japanese customers, approval timelines remain unpredictable. US tariffs on Chinese wafer substrates escalated to 70% by March 2025 under multiple authorities. Although the US Supreme Court invalidated IEEPA-based tariffs in February 2026, Section 301 tariffs remain, and replacement tariffs are threatened. The cumulative effect collapsed North American revenue from 8% of total worldwide revenue in 2024 to approximately 2% in 2025. Tariffs paid were $0.3M in 2025, down from $1.0M in 2024 and 2023, reflecting reduced US sales volume. China's December 2025 amendments to the Foreign Trade Law expand government authority over trade policy, adding further uncertainty.
All manufacturing occurs in China, exposing AXT to mandatory government shutdowns due to air pollution. Historical shutdowns, such as the 10-day closure in Q1 2018, directly delayed shipments and reduced revenue. The relocation of GaAs and Ge production lines from Beijing to new sites in DingXing and Kazuo is complete, but unforeseen manufacturing issues at new sites remain a risk. Raw material joint ventures in China face tightening hazardous materials regulations; gallium arsenide was added to the hazardous substances list in 2015, requiring additional permits. Joint venture partners' operational problems or regulatory violations could disrupt supply and trigger impairment charges.
Gross margin is highly volatile, ranging from negative 6.4% in Q1 2025 to 22.3% in Q3 2025, driven by product mix, factory utilization, tariffs, and raw material costs. The pending Tongmei STAR Market IPO carries a ~$49M redemption risk if CSRC approval fails. AXT's stock price experienced extreme volatility in Q4 2025, with significant price and volume increases unrelated to business announcements. The company holds $50.5M in US federal NOL carryforwards, but ownership changes could limit their use. Foreign exchange exposure from RMB, JPY, and EUR-denominated sales creates periodic gains and losses.
Silicon-based technologies like SOI have already displaced GaAs in RF mobile phone applications, and further silicon substitution threatens specialty substrate demand. The semiconductor cycle caused a severe revenue decline from $39.7M in Q1 2022 to $17.4M in Q3 2023 during an inventory correction. Competitors including Sumitomo, JX, and Freiberger have greater resources, and China's push for self-sufficiency may spawn new domestic competitors. Average selling prices decline 5-10% annually for certain products, pressuring margins.
A shareholder class action filed in May 2024 alleges securities law violations, with a motion to dismiss pending. A related derivative lawsuit was dismissed in March 2025 but is under appeal. Both matters create defense cost exposure and management distraction. PCAOB inspection access for the independent auditor remains a compliance consideration, though the current auditor is fully inspected.
AXT, Inc. reported net cash provided by operating activities of $9.2 million for the fiscal year ended December 31, 2025, a 35% increase from $6.8 million in 2024. This improvement was primarily driven by a net loss of $5.1 million adjusted for non-cash charges including $8.8 million in depreciation and amortization and $4.1 million in stock-based compensation. Working capital changes provided a tailwind, with a $3.4 million decrease in inventories and a $2.8 million increase in accounts payable, partially offset by a $1.2 million increase in accounts receivable.
Capital expenditures totaled $17.7 million in 2025, significantly exceeding operating cash flow and resulting in negative free cash flow. The elevated capex was directed toward the construction of a new manufacturing facility in China, reflecting a strategic investment phase. Investing activities also included a $1.0 million purchase of a cost method investment.
Financing activities provided a substantial $93.6 million inflow, dominated by $95.0 million in net proceeds from a public equity offering. This was partially offset by $1.4 million in tax withholdings on vested restricted stock units. Short-term loan proceeds of $62.8 million were fully offset by repayments of $47.3 million and a $15.5 million decrease in restricted cash. The company did not pay dividends or repurchase shares during the period. Overall, cash and cash equivalents surged to $120.3 million from $22.8 million at year-end 2024, bolstered by the equity raise.